Post-marketing phase 4 safety & tolerability study of Breztri aerosphereTM in Indian patients with Chronic Obstructive Pulmonary Disease - INDOS-B

Study identifier:D5980L00017

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

Post-marketing phase IV, multicenter, prospective study to observe the safety and tolerability of Breztri aerosphereTM containing a fixed dose combination of Budesonide 160 mcg/ Glycopyrronium 7.2 mcg/ Formoterol fumarate dehydrate 5 mcg in patients with moderate to severe Chronic Obstructive Pulmonary Disease

Medical condition

Moderate to severe COPD

Phase

Phase 4

Healthy volunteers

No

Study drug

Breztri Aerosphere

Sex

All

Estimated Enrollment

150

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 01 Sept 2024
Estimated Primary Completion Date: 01 Oct 2025
Estimated Study Completion Date: 01 Oct 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria